Search

The widespread adoption of fuel cells requires exhaustive screening for highly active and durable Pt-based catalysts for the oxygen reduction reaction. Now a binary descriptor based on experimental parameters extracted from X-ray absorption spectroscopy is used to predict the catalytic activity and stability of a wide range of Pt-alloy catalysts.

The mechanism of heterogeneous aqueous-phase aerobic oxidations remains under debate. Now, it has been shown that the reaction can be described as two coupled electrochemical half-reactions for oxygen reduction and substrate oxidation, and the thermochemical rates can be derived from the electrochemical half-reactions via the application of mixed potential theory.

Inexpensive Fe–N–C single-atom catalysts are a promising solution to replace costly Pt-based cathode catalysts in fuel cells, but they typically suffer from low durability. Now, the degradation mechanisms of Fe–N–C catalysts are identified under operando conditions as a function of time, and potential solutions are proposed.

The activity of PD-1 blockade in patients with sarcoma has been modest so far. Here, the authors report the results of a pilot clinical trial to assess the efficacy and safety of bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, in combination with the PD1 blockade (nivolumab) in patients with locally advanced or metastatic high-grade sarcoma.

In a phase 1 trial of patients with advanced systemic mastocytosis, avapritinib, a selective KIT inhibitor, was generally well tolerated, elicited durable clinical responses and led to reductions in mast cell disease burden.

While the electrochemical conversion of CO₂ to highly reduced products is unique to copper, there are still gaps in understanding copper catalysts’ efficacy. Here, authors find that co-electrolysis of CO₂ with O₂ can enhance copper’s catalytic activities.

Here the authors design an electrolysis reactor to generate H₂O₂ which could be further catalytically activated by Cu single atoms to yield hydroxyl radicals. Combining the two reactions enables a system that could treat organic wastewater, providing a path toward sustainable advanced oxidation processes.

In a phase 2 trial, nivolumab achieved a response rate of 58% in patients with mismatch-repair-deficient gynecological cancers, meeting the primary endpoint, and genomic and immunologic features correlated with response.

In cohort B of the phase 2 SWOG S1512 trial, pembrolizumab monotherapy in patients with unresectable desmoplastic melanoma elicited a complete response rate of 37% and an objective response rate of 89%, supporting a new treatment option for this tumor type.

In a phase 3 trial, selection of non-small cell lung cancer patients based on high blood-based tumor mutation burden did not improve clinical response to the checkpoint blockade inhibitor atezolizumab, as compared with standard of care platinum-based chemotherapy.

Exploratory ctDNA analyses from the phase 3 INTRIGUE trial indicate that ripretinib may provide benefits in patients with advanced gastrointestinal stromal tumors with KIT exon 11 + 17/18 mutations

Results of a multicentre phase 1 clinical trial evaluating treatment with the engineered herpes simplex virus VG161 in advanced liver cancer indicate a good safety profile and promising efficacy.

In a phase 2 trial of pembrolizumab and cabozantinib in patients with advanced head and neck cancer, a high clinical benefit rate was achieved, which positively correlated with levels of CD8⁺ T cell infiltration but not tumor mutational burden.

Highly active oxygen reduction catalysts that are free of platinum group metals would decrease the cost of fuel cells. Here, the authors report on a commercial Fe–N–C-based catalyst that can replace platinum group metal-based catalysts in the cathodes of anion-exchange membrane fuel cells without a severe loss of performance.

Sacituzumab Govitecan, TROP-2 targeted antibody drug conjugate, is effective for the treatment of breast cancer, but its potential utility for the treatment of breast cancer brain metastasis and recurrent glioblastoma is unclear. Here, the authors present a window-of-opportunity phase 0 trial reporting the central nervous system penetrance and intracranial efficacy of Sacituzumab Govitecan.

Radiotherapy is a key component of glioblastoma therapy, however, difficulties in delivering high doses to tumours cells while preserving healthy tissues risks limits its success. Here, the authors report a phase I dose escalation study investigating convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL), chelated-186Re encapsulated in nanoliposomes, in patients with recurrent, high-grade malignant glioma.

In the phase 2 HUDSON study, patients with advanced non-small-cell lung cancer received anti-PD-L1 combined with biomarker-guided therapy targeting ATR kinase, PARP, STAT3 or CD73, leading to encouraging clinical benefit in response to combination of the ATR kinase inhibitor ceralasertib with durvalumab.

In a phase 2 trial of adults with neurofibromatosis type 1 and inoperable/growing plexiform neurofibromas, treatment with the MEK inhibitor selumetinib resulted in an objective response rate of 63.6% and improvement in other patient outcomes, with additional biopsy-based data providing further information on drug activity.

Zhao et al. used single-cell and spatial multiomics data analysis of human and mouse lung adenocarcinoma tumors and cell lines to reveal TP53 mutation-associated changes in cancer cells and their microenvironment.

Patients with BRAF^V600E-mutated colorectal cancer have encouraging overall response rates to inhibition of PD-1, BRAF and MEK, with translational analyses suggesting that induction of tumor-intrinsic programs and immune programs contributes to improved outcomes via MAPK inhibition.

The deficiency of MTAP, an enzyme of the adenine salvage pathway, occurs in some cancers. Here the authors perform a small cohort phase II clinical trial with metastatic MTAP-deficient urothelial cancer (UC) and show an increased overall response when comparing to MTAP-proficient UC patients.

Perovskite oxides are attractive candidates as catalysts for water electrolysis however their rational design is rare. Here, the authors report a series of cobaltite perovskites where the covalency of the Co-O bond and concentration of oxygen vacancies are controlled, and assess their catalytic performance.

While strain engineering via support modification is a powerful strategy to tune catalytic properties, it is complex to control for immobilized molecular complexes. Now the curvature of carbon nanotubes is leveraged to induce strain to metal phthalocyanine complexes and boost their electrocatalytic activity

Neoadjuvant treatment with nivolumab plus ipilimumab is well tolerated and demonstrates clinical efficacy in patients with early stage lung cancer.

Anticancer therapies that target the HIF oxygen-sensing pathways are moving into the clinic, in particular in kidney cancer.

Wireless tracking of neuronal activity in social groups of mice identifies neurons in the anterior cingulate that hold representations of an animal’s social rank and can influence the competitive effort that the animal exerts.

With redox-linked synthetic biology and electrobiofabrication, electronic information can be transmitted in a bidirectional manner between biology and electronics. Here the authors design an electrogenetic platform that allows real time electronic control of biological functions from proteins and gene circuits to cell consortia.

Stereotactic ablative radiotherapy (SABR) is standard-of-care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC), however the risk of systemic recurrences remains high. Here the authors report the results of a phase I study testing the addition of atezolizumab (anti-PD-L1) to SABR in high risk, medically inoperable, early-stage, NSCLC.